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Abstract 
INTRODUCTION: People with end-stage kidney disease (ESKD) have up to 30-fold higher risk of stroke 
than the general population. OBJECTIVE: To determine risk factors associated with stroke death in the 
ESKD population. METHODS: We identified all patients with incident ESKD in Australia (1980-2013) and 
New Zealand (1988-2012) from the Australian and New Zealand Dialysis and Transplant Registry 
(ANZDATA) registry. We ascertained underlying cause of death from data linkage with national death 
registries and risk factors from ANZDATA. Using a competing risks multivariable regression model, we 
estimated cumulative incidence of stroke and non-stroke deaths, and risk factors for stroke deaths 
(adjusted sub-HR, SHR). RESULTS: We included 60 823 people with ESKD. There were 941 stroke deaths 
and 33 377 non-stroke deaths during 381 874 person-years of follow-up. Overall, the cumulative incidence 
of stroke death was 0.9% and non-stroke death was 36.8% 5 years after starting ESKD treatment. The risk 
of stroke death was higher at older ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR 1.41, 95% CI 
1.21 to 1.64), in people with cerebrovascular disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD caused 
by hypertensive/renovascular disease (SHR 1.39, 95% CI 1.09 to 1.78) or polycystic kidney disease (SHR 
1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39) 
and receiving dialysis (transplant vs haemodialysis SHR 0.27, 95% CI 0.09 to 0.84). CONCLUSION: 
Patients with ESKD with higher risk of stroke death are older, women, with cerebrovascular disease, with 
hypertensive/renovascular or polycystic kidney disease cause of ESKD, with earlier year of ESKD 
treatment and receiving dialysis. These groups may benefit from targeted stroke prevention interventions. 
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AbstrACt
Introduction People with end-stage kidney disease 
(ESKD) have up to 30-fold higher risk of stroke than the 
general population.
Objective To determine risk factors associated with stroke 
death in the ESKD population.
Methods We identified all patients with incident ESKD 
in Australia (1980–2013) and New Zealand (1988–2012) 
from the Australian and New Zealand Dialysis and 
Transplant Registry (ANZDATA) registry. We ascertained 
underlying cause of death from data linkage with national 
death registries and risk factors from ANZDATA. Using 
a competing risks multivariable regression model, we 
estimated cumulative incidence of stroke and non-stroke 
deaths, and risk factors for stroke deaths (adjusted sub-
HR, SHR).
results We included 60 823 people with ESKD. There 
were 941 stroke deaths and 33 377 non-stroke deaths 
during 381 874 person-years of follow-up. Overall, the 
cumulative incidence of stroke death was 0.9% and 
non-stroke death was 36.8% 5 years after starting ESKD 
treatment. The risk of stroke death was higher at older 
ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR 
1.41, 95% CI 1.21 to 1.64), in people with cerebrovascular 
disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD 
caused by hypertensive/renovascular disease (SHR 1.39, 
95% CI 1.09 to 1.78) or polycystic kidney disease (SHR 
1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD 
treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39) and 
receiving dialysis (transplant vs haemodialysis SHR 0.27, 
95% CI 0.09 to 0.84).
Conclusion Patients with ESKD with higher risk of 
stroke death are older, women, with cerebrovascular 
disease, with hypertensive/renovascular or polycystic 
kidney disease cause of ESKD, with earlier year of ESKD 
treatment and receiving dialysis. These groups may benefit 
from targeted stroke prevention interventions.
IntrOduCtIOn 
Compared with the general population, 
people with end-stage kidney disease (ESKD) 
have a substantially reduced life expectancy 
with cardiovascular disease killing more than 
50% of people receiving renal replacement 
therapy (RRT).1–3 Globally in developed coun-
tries, mortality from cardiovascular diseases 
has declined since the 1960s, with heart disease 
deaths declining by 56% in the USA between 
1950 and 1996 and all-cause cardiovascular 
deaths declining by more than 70% in the 
Netherlands and 60% in the UK and Ireland 
from 1980 to 2009. Despite people with ESKD 
having a 5 to 30-fold increased risk of stroke 
compared with the general population, the 
epidemiology of stroke death in ESKD is far 
less clear. An Australian registry-based study 
reported that for people with ESKD, the rela-
tive risk of death from cardiovascular disease 
between 1992 and 2005 increased compared 
with the general population, despite absolute 
cardiovascular death rates falling.4 Another 
contemporary Taiwanese case–control study 
reported a greater than twofold risk of 30-day 
mortality following a stroke in people with 
ESKD compared with propensity-matched 
controls.5 
Such differences in outcomes between the 
general population and people with ESKD 
following a stroke could arise because of 
strengths and limitations of this study
 ► This study used a large, population-based cohort in-
cluding the entire population with end-stage kidney 
disease (ESKD) in Australia and New Zealand.
 ► The largest multinational study examining risk fac-
tors for stroke mortality in people with ESKD to date.
 ► Data linkage with the national death registries al-
lowed legal cause of death to be ascertained for 
all patients, although probabilistic data linkage for 
Australian patients with ESKD may lead to some pa-
tients being incorrectly linked.
 ► Detailed patient information on the use of stroke 
prevention drugs or other factors relating to their 
risk of stroke was not available, such as family his-
tory of stroke and atrial fibrillation.
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differences in the prevalence and severity of underlying 
traditional stroke risk factors including hypertension, 
diabetes and atrial fibrillation.6 7 Stroke case severity may 
also differ, as might the effectiveness and access to preven-
tative treatments (including aspirin, ACE inhibitors, anti-
coagulants and statins) and acute stroke interventions 
including thrombolysis. Risk factors specific to people 
with ESKD may also exist: accelerated calcific athero-
sclerosis (from disordered bone metabolism), platelet 
dysfunction, anaemia.1 8 In addition, dialysis-associated 
osmotic fluid and electrolyte shifts or exposure to glucose 
degradation products from peritoneal dialysis (PD) fluid 
may all alter normal pathological glial scar resolution and 
affect functional outcomes following stroke.9 For people 
with kidney transplants, in addition to traditional cardio-
vascular risk factors, graft function and albuminuria as 
well as the side effects of immunosuppressive medicines 
might all modify stroke outcomes.10
The aims of our study were to establish robust estimates 
of stroke and non-stroke death incidence in people with 
ESKD, and to identify risk factors associated with dying 
after a stroke.
MethOd
study design and setting
We performed a population-based cohort study of all 
adults and children starting RRT for treatment of ESKD in 
Australia (1 January 1980 to 31 December 2013) and New 
Zealand (1 January 1988 to 31 December 2012). Australia 
(population 24.8 million in 2017) and New Zealand 
(population 4.7 million in 2017) are broadly comparable 
in racial make-up and population demographics, where 
approximately 75% are from a European, Australian or 
New Zealand cultural background.11 12 Both countries have 
a universal healthcare system that provides free medical 
care in public health systems. All deaths occurring in each 
country are reported to the Births, Deaths and Marriages 
Registry with a medical certificate for the cause of death 
completed by a medical doctor which is then coded to the 
international standard, the International Statistical Classi-
fication of Diseases and Related Health Problems (ICD), 
codes by a qualified clinical coder, detailing both the 
underlying and secondary causes of death. The under-
lying cause of death is considered as the disease or condi-
tion which initiated the sequence of events resulting in 
death. Secondary or contributing causes of death are 
other diseases or conditions that contributed to the death 
but were not the underlying cause.
Participants, data linkage and death outcomes
People with ESKD
The Australia and New Zealand Dialysis and Transplant 
Registry (ANZDATA) prospectively collects data from 
all dialysis and transplant centres in Australia and New 
Zealand. Data are collected either via web based or 
printed survey forms in real time as key events occur 
for each patient with ESKD. Core data collected include 
demographics (age, sex, country, racial background, 
body mass index, BMI and smoking history), comorbid-
ities (cerebrovascular disease, diabetes, coronary artery 
disease, peripheral artery disease and previous malig-
nancy) and modality of treatment for ESKD (type of 
dialysis or transplant, date initiated and cause of kidney 
failure). ANZDATA data collection, remit and validation 
has been previously described elsewhere.13
Data linkage
We used data linkage of ANZDATA with each of the 
national death registries in Australia and New Zealand 
to determine the date and underlying cause of death for 
people with ESKD. In Australia, patients with ESKD were 
linked with the National Death Index, which records all 
deaths from 1980 and is maintained by the Australian 
Institute of Health and Welfare (AIHW). The Austra-
lian Bureau of Statistics (ABS) retrieves information on 
all deaths and their causes from the Births, Deaths and 
Marriages Registry in each state and territory. The ABS 
collates these data and a clinical coder then codes the 
causes of death to an international standard ICD.14 The 
National Centre for Classification in Health has devel-
oped an Australian modification version, currently in its 
Tenth Revision which is referred to as ICD-10-AM. We 
used probabilistic record linkage for Australian patients 
with ESKD, matching on date of birth, sex and full name. 
In New Zealand, patients with ESKD were linked with the 
Mortality Collection database, which collects information 
on all deaths from 1988 and is maintained by the New 
Zealand Ministry of Health. The Ministry receives infor-
mation from the Births, Deaths and Marriages Registry 
as well as additional information from medical certifi-
cates and coroners’ reports to classify causes of death 
into ICD-10-AM. We used deterministic linkage for New 
Zealand patients with ESKD, matching on the National 
Health Index number. Hence, our analysis was restricted 
by the available data in the national death registries. We 
included all patients with incident ESKD in Australia 
during 1980–2013 and in New Zealand during 1988–2012.
Data linkage was performed by the AIHW and New 
Zealand Ministry of Health using best-practice priva-
cy-preserving protocols. After data linkage was complete, 
only de-identified data were made available for the 
purposes of this study. 
Death ascertainment, stroke definition and cause of death
Causes of death were determined using ICD-10-AM diag-
nosis codes provided in the underlying cause of death 
from the Australian and New Zealand national death 
registries. All-cause stroke deaths included subarachnoid 
haemorrhage (I60.0–I60.9), intracerebral haemorrhages 
(I61.0–I61.9), intracranial haemorrhages (I62.0–I62.9), 
ischaemic strokes (I63.0–I63.9), unspecified strokes 
(I64.0–I64.9) and, transient cerebral ischaemic attacks 
and related syndromes (G45.0–G45.9). Prior to 1997, 
the ninth revision of ICD was implemented. There is 
little evidence for significant differences in stroke coding 
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between revisions, with agreement being over 90%.15 16 
All other causes of death were considered as non-stroke 
deaths.
Patient and public involvement
We used retrospective registry data for this study, hence 
study participants were not involved in the recruitment or 
design of the study. Patient advisers were also not involved 
in this study.
statistical analyses
We summarised the main causes of death by deriving the 
leading causes of death, defined by ICD-10-AM codes.17 
We also estimated the crude mortality rates for stroke 
and non-stroke deaths, overall and stratified by patient 
demographics.
We used Fine and Gray competing risks regression 
models to evaluate risk factors associated with stroke 
death.18 Time was measured from the start date of ESKD 
treatment until a participant died or 31 December 2013 
(Australian participants) or 31 December 2012 (New 
Zealand participants), whichever came first. As proba-
bilistic record linkage may lead to a small proportion of 
incorrect links,19 Australian patients were censored at the 
ANZDATA date of death if ANZDATA considered the 
patient had died and the national death registry had not 
captured any death. For the analysis of stroke deaths, all 
non-stroke deaths were considered as competing events. 
For comparison, we also similarly conducted an analysis 
of non-stroke deaths, with stroke deaths considered as 
competing events. For both the stroke and non-stroke 
analyses, we used the same covariates, selected a priori 
including: age at initiation of ESKD treatment, sex, year 
of initiating ESKD treatment, country, racial background, 
BMI category (underweight, ≤18.4 kg/m2; normal, 18.5–
24.9 kg/m2; overweight, 25.0–29.9 kg/m2 and obese, 
≥30.0 kg/m2), initial ESKD treatment modality, comor-
bidities, smoking status and cause of ESKD. Univariable 
models were fitted for each covariate, and the multivari-
able models included all covariates. The cumulative inci-
dence was estimated from the final multivariate model, by 
sex and year of initiating ESKD treatment, adjusting for 
all other covariates except BMI.
There were no missing data, except for BMI. Missing 
values for BMI were imputed using chained equations 
with five iterations. To impute, we used the same vari-
ables as those used in the competing risks analyses, then 
converted those BMI values into categories for the regres-
sion models.
We conducted a further three sensitivity analyses to 
determine: (1) whether risk factors for any stroke death 
were similar to risk factors for fatal ischaemic stroke and 
fatal haemorrhagic stroke; (2) whether risk factors were 
the same when stroke death was defined as underlying 
cause, or secondary cause when kidney failure was indi-
cated as the underlying cause and (3) whether ever trans-
planted with a kidney as a time-varying covariate produced 
different model estimates. For these sensitivity analyses, 
we used cause-specific Cox regression models to evaluate 
associated risk factors and used the same covariates and 
definition of time at risk as described in the main analysis.
Data were analysed using Stata V.14 (Stata).
results
Patient characteristics
We identified a total of 62 296 people with incident ESKD 
in Australia and New Zealand between 1980 and 2013. 
Of these, 1473 New Zealand patients initiated RRT prior 
to 1988 or after 2012, and so could not be linked. The 
remaining 60 823 patients with ESKD were included in the 
analysis (figure 1). The fact of death for the majority of 
patients was similar between ANZDATA and the national 
death registries, where disagreement occurred for 7.6% 
of Australian patients and 5.5% of New Zealand patients. 
There were 467 patients considered to be lost to follow-up 
in ANZDATA, where 57 patients were considered to have 
died in the national death registry. There were 381 874 
person-years (PYs) of follow-up, with a median follow-up 
time of 4.0 years (IQR 1.7–8.4 years).
During the study period, 26 505 patients (43%) 
remained in active follow-up and 34 318 patients (57%) 
died (table 1). Of the patients who died, 33 377 patients 
died of non-stroke causes (97.3%) and 941 patients 
(2.7%) died of stroke. In our entire study population, 
two-thirds (69%) were aged 50 years or older at ESKD, 
with a median age of 59 years (IQR 46–69). Most were 
from Australia (85%), were male (59%), had a Caucasian 
background (76%) and had started treatment for ESKD 
Figure 1 Patient flow chart of data linkage process and 
inclusion into analysis. ANZDATA, Australian and New 
Zealand Dialysis and Transplant Registry; ESKD, end-stage 
kidney disease.
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Table 1 Characteristics of participants with end-stage kidney disease (ESKD), overall and by stroke and non-stroke deaths
Characteristics
Stroke deaths Total
Non-stroke deaths  
Total Total
n (%)* n (%)* n (%)*
Total, (%) 941 (2)† 33 377 (55)† 60 823 (100)
Age at RRT initiation (years)
  ≤29 25 (3) 1150 (3) 5088 (8)
  30–49 177 (19) 5399 (16) 13 807 (23)
  50–64 329 (35) 11 417 (34) 19 980 (33)
  65–74 261 (28) 9658 (29) 13 842 (23)
  ≥75 149 (16) 5753 (17) 8106 (13)
  Median (IQR) 62 (52–71) 63 (53–72) 59 (46–69)
Sex
  Female 472 (50) 13 901 (42) 25 042 (41)
  Male 469 (50) 19 476 (58) 35 781 (59)
Year of ESKD
  ≤1995 379 (40) 11 515 (35) 15 382 (25)
  1996–2005 367 (39) 14 700 (44) 22 115 (36)
  2006–2013 195 (21) 7162 (21) 23 326 (38)
Country
  Australia 819 (87) 28 173 (84) 51 451 (85)
  New Zealand 122 (13) 5204 (16) 9372 (15)
Racial background
  European 737 (78) 26 286 (79) 46 025 (76)
  Indigenous Oceania 122 (13) 5244 (16) 9743 (16)
  Asian 78 (8) 1667 (5) 4357 (7)
  African and Middle East 4 (<0.5) 154 (<0.5) 492 (1)
  Peoples of the America 0 (−) 4 (<0.1) 19 (<0.1)
  Other‡ 0 (−) 22 (<0.1) 187 (<0.4)
Body mass index
  Underweight (≤18.4) 32 (3) 1274 (4) 2702 (4)
  Normal (18.5–24.9) 353 (38) 10 662 (32) 19 866 (33)
  Overweight (25.0–29.9) 209 (22) 8670 (26) 16 641 (27)
  Obese (≥30) 132 (14) 6561 (20) 13 772 (23)
  Not collected 215 (23) 6210 (19) 7842 (13)
Comorbidities at ESKD
  Cerebrovascular disease 246 (26) 5393 (16) 7676 (13)
  Diabetes 313 (33) 12 863 (39) 21 717 (36)
  Coronary artery disease 372 (40) 14 310 (43) 20 785 (34)
  Peripheral artery disease 252 (27) 9487 (28) 13 373 (22)
  Previous malignancy 208 (22) 9707 (29) 15 788 (26)
Smoking status
  Current/former 413 (44) 16 081 (48) 28 389 (47)
  Never 345 (37) 11 955 (36) 25 861 (43)
  Unknown 183 (19) 5341 (16) 6573 (11)
Cause of renal failure
  Diabetes 249 (26) 9925 (30) 16 909 (28)
Continued
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in 1996 or later (74%). The majority of patients had a 
normal (33%) or overweight (27%) BMI, where only 4% 
were underweight. The BMI was not collected for 13% 
of patients, the large majority (95%) of whom reached 
ESKD prior to 1996. The main cause of ESKD was diabetes 
(28%), followed by glomerulonephritis/IgA nephropathy 
(27%), other causes of ESKD (26%), hypertension/renal 
artery disease (12%) and polycystic kidney disease (7%). 
The reason for other causes of ESKD included uncer-
tain diagnosis (23%), analgesic nephropathy (18%) and 
reflux nephropathy (16%).
deaths
There were a total of 34 318 deaths since initiation of 
ESKD treatment, with a crude rate of 89.9 (95% CI 88.9 
to 90.8) per 1000 PYs. The top four leading causes of 
death were recorded as diabetes (18%), coronary heart 
disease (18%), kidney failure (13%) and glomerular 
disease (5%). Stroke was the sixth leading cause of death 
since RRT, with a total 941 stroke deaths, corresponding 
to a crude rate of 2.5 (95% CI 2.3 to 2.6) per 1000 PYs 
(table 2). Stroke deaths were due to: 108 (11%) isch-
aemic strokes; 259 (28%) intracerebral haemorrhages; 90 
(10%) intracranial haemorrhages; 68 (7%) subarachnoid 
haemorrhages; 114 (12%) transient cerebral ischaemic 
attacks and related syndromes and 302 (32%) unspeci-
fied strokes (online supplementary appendix 1).
The highest rate of stroke death since initiation of ESKD 
treatment was among those with known cerebrovascular 
disease at 9.1 (95% CI 8.0 to 10.3) per 1000 PYs, followed 
by those aged 75 years or older at 6.6 (95% CI 5.6 to 7.7) 
per 1000 PYs (table 2). In comparison, the highest rate 
of non-stroke death since initiation of ESKD treatment 
was among those aged 75 years or older at 254.5 (95% 
CI 248.0 to 261.2) per 1000 PYs, followed by those with 
cerebrovascular disease at 199.0 (95% CI 193.7 to 204.4) 
per 1000 PYs.
risk factors for stroke mortality
The multivariable model suggested a higher risk of stroke 
death was associated with older age, female sex, earlier 
year of ESKD, normal BMI range, presence of pre-ex-
isting cerebrovascular disease, no previous malignancy, 
ESKD treatment with haemodialysis (HD) compared with 
transplant and hypertension/renal artery disease or poly-
cystic kidney disease as the cause of ESKD compared with 
glomerulonephritis/IgA nephropathy (table 3).
Older age was associated with a higher risk of stroke 
death, where patients aged 75 years or older were 92% 
sub-HR (SHR 1.92, 95% CI 1.45 to 2.55) more likely to die 
from stroke death compared with those aged 30–49 years 
(p<0.001). Females were 41% more likely to die of stroke 
death compared with males (SHR 1.41, 95% CI 1.21 to 
1.64; p<0.001). There was a decreasing trend in the risk 
of stroke death overtime, where patients initiating ESKD 
treatment in ≤1995 and 1996–2005 were 93% (SHR 1.93, 
95% CI 1.56 to 2.39) and 30% (SHR 1.30, 95% CI 1.09 to 
1.55), respectively, more likely to die from stroke death 
compared with those in 2006–2013 (p<0.001). Patients 
had over two times the increased risk of stroke death if 
they had pre-existing cerebrovascular disease (SHR 2.39, 
95% CI 1.99 to 2.87; p<0.001) and were 36% less likely to 
die of stroke if they had a previous malignancy (SHR 0.64, 
95% CI 0.53 to 0.78; p<0.001). There was no difference in 
the risk of stroke death for those who initiated PD (SHR 
0.85; 95% CI 0.72 to 1.01) compared with HD. However, 
transplant patients were 73% less likely to die of stroke 
compared with HD patients (SHR 0.27, 95% CI 0.09 to 
0.84). Similar estimates for the risk of stroke death were 
produced when transplant was considered a time-varying 
covariate (HR 0.24, 95% CI 0.17 to 0.32; p<0.001) (online 
supplementary appendix 2). The cause of ESKD was also 
significantly associated with stroke mortality (p=0.020). 
Patients with hypertension/renal artery disease or 
Characteristics
Stroke deaths Total
Non-stroke deaths  
Total Total
n (%)* n (%)* n (%)*
  Hypertension/renal artery 
disease
169 (18) 4763 (14) 7264 (12)
  Glomerulonephritis/IgA 
nephropathy
211 (22) 7626 (23) 16 632 (27)
  Polycystic kidney disease 71 (8) 1623 (5) 4003 (7)
  Other 241 (26) 9440 (28) 16 015 (26)
Transplanted at beginning of 
study
4 (<0.5) 151 (<0.5) 1649 (3)
Transplanted during study 154 (16) 4978 (15) 16 068 (26)
*Column percentage.
†Row percentage.
‡Includes Australian Aboriginal, Maori, Torres Strait and Pacific Islander.
RRT, renal replacement therapy.
Table 1 Continued 
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Table 3 Summary of the adjusted sub-HR (SHR) estimates for the competing risks model with stroke deaths as the main 
event and non-stroke deaths as the competing event
Stroke death Non-stroke death
SHR (95% CI) P value SHR (95% CI) P value
Age at study entry (years) <0.001 <0.001
  ≤29 0.43 (0.26 to 0.70) – 0.39 (0.37 to 0.43) –
  30–49 Ref Ref
  50–64 1.47 (1.16 to 1.86) – 1.96 (1.89 to 2.04) – 
  65–74 1.82 (1.42 to 2.33) – 3.23 (3.10 to 3.37) – 
  ≥75 1.92 (1.45 to 2.55) – 4.68 (4.45 to 4.91) –
Sex
  Male Ref Ref
  Female 1.41 (1.21 to 1.64) <0.001 1.05 (1.02 to 1.08) <0.001
Year of ESKD <0.001 <0.001
  ≤1995 1.93 (1.56 to 2.39) – 1.39 (1.33 to 1.45) –
  1996–2005 1.30 (1.09 to 1.55) – 1.29 (1.25 to 1.33) –
  2006–2013 Ref Ref
BMI category <0.001 <0.001
  Underweight 0.78 (0.54 to 1.12) – 1.24 (1.16 to 1.33) –
  Normal Ref Ref
  Overweight 0.76 (0.64 to 0.90) – 0.93 (0.90 to 0.96) –
  Obese 0.61 (0.49 to 0.76) – 0.98 (0.95 to 1.02) – 
Racial background
  Non-white Ref Ref
  White 0.88 (0.73 to 1.06) 0.182 1.11 (1.07 to 1.15) <0.001
Comorbidities at ESKD
  Cerebrovascular disease
  Present 2.39 (1.99 to 2.87) <0.001 1.13 (1.09 to 1.17) <0.001
  Coronary artery disease
  Present 1.00 (0.83 to 1.20) 0.960 1.38 (1.34 to 1.42) <0.001
  Peripheral artery disease
  Present 0.90 (0.74 to 1.09) 0.299 1.30 (1.25 to 1.34) <0.001
  Previous malignancy
  Present 0.64 (0.53 to 0.78) <0.001 0.90 (0.88 to 0.93) <0.001
Smoking status
  Never/unknown Ref Ref
  Current/former 1.06 (0.91 to 1.24) 0.441 1.18 (1.15 to 1.21) <0.001
First dialysis module 0.015 <0.001
  HD Ref Ref
  PD 0.85 (0.72 to 1.01) – 1.00 (0.97 to 1.03) – 
  Transplant 0.27 (0.09 to 0.84) – 0.26 (0.22 to 0.31) –
Cause of renal failure 0.020 <0.001
  Diabetes 1.23 (0.99 to 1.54) – 1.60 (1.54 to 1.66) –
  Hypertension/ 
renal artery disease
1.39 (1.09 to 1.78) – 1.23 (1.18 to 1.29) –
  Glomerulonephritis/ 
IgA nephropathy
Ref Ref
  Polycystic kidney disease 1.38 (1.00 to 1.90) – 0.72 (0.68 to 0.76) –
Continued
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polycystic kidney disease were 39% (SHR 1.50, 95% CI 
1.20 to 1.87) and 38% (SHR 1.38, 95% CI 1.00 to 1.90), 
respectively, more likely of stroke death compared with 
those with glomerulonephritis/IgA nephropathy. The 
unadjusted estimated risk of stroke death is presented in 
online supplementary appendix 3.
In the sensitivity analysis, the risk of fatal ischaemic 
stroke was not associated with BMI, cerebrovascular 
disease, previous malignancy or HD compared with trans-
plant (online supplementary appendix 4). White racial 
background and coronary artery disease were associated 
with an increased risk of ischaemic stroke death, which 
were not risk factors for all-cause stroke death. Year of 
ESKD was also not associated with the risk of fatal isch-
aemic or haemorrhagic stroke. The risk factors for fatal 
haemorrhagic stroke were all similar to the risk factors 
for all-cause stroke death, except for cause of renal failure 
(online supplementary appendix 4). Cause of renal 
failure was not associated with the risk of fatal haemor-
rhagic stroke.
There were an additional 694 stroke deaths when 
all-cause stroke death was defined as the underlying cause 
or secondary cause when kidney failure was the under-
lying cause. All risk factors associated with the extended 
definition for all-cause stroke were the same as those 
identified in the main analysis, except for peripheral 
artery disease (online supplementary appendix 5). In the 
sensitivity multivariate model, patients with pre-existing 
peripheral artery disease were at an increased risk for 
all-cause stroke mortality.
risk factors for non-stroke mortality
The multivariable model suggested that a higher risk of 
non-stroke death was associated with older age, female 
sex, earlier year of ESKD, underweight or normal BMI 
range, Caucasian background, presence of comorbidi-
ties including cerebrovascular disease, coronary artery 
disease, peripheral artery disease and no previous malig-
nancy, current or former smoker, dialysis compared with 
transplant and cause of ESKD including diabetes, hyper-
tension/renal artery disease or other causes (table 3).
Patients initiating ESKD treatment with a transplant 
were associated with a 73% lower risk of non-stroke death 
compared with those initiating HD (SHR 0.27, 95% CI 
0.23 to 0.32; p<0.001). Similar estimates for the risk of 
non-stroke death were produced when transplant was 
considered a time-varying covariate (HR 0.30, 95% CI 
0.29 to 0.32; p<0.001) (online supplementary appendix 
2). The cause of ESKD was also significantly associated 
with non-stroke mortality (p<0.001). A higher risk of 
non-stroke mortality was associated with diabetes (SHR 
1.60, 95% CI 1.54 to 1.65), hypertension/renal artery 
disease (SHR 1.24, 95% CI 1.19 to 1.29) or other causes 
(SHR 1.38, 95% CI 1.33 to 1.42) compared with glomeru-
lonephritis/IgA nephropathy as the cause of ESKD. Those 
with polycystic kidney disease were 24% less likely (SHR 
0.76, 95% CI 0.72 to 0.80) to die of non-stroke compared 
with those with glomerulonephritis/IgA nephropathy. 
The unadjusted estimated risk of non-stroke death is 
presented in online supplementary appendix 3.
Cumulative incidence of death
The estimated cumulative incidence of stroke mortality 
since RRT was relatively low at 0.5% at 2 years, while the 
non-stroke mortality was substantially higher at 15.5% at 
2 years. At 5 years, the cumulative incidence increased to 
0.9% for stroke and 36.8% for non-stroke mortality.
The cumulative incidence of stroke or non-stroke death 
differed by sex, where females consistently had a higher 
cumulative incidence (figure 2A). For stroke mortality, 
the cumulative incidence at 2 years in males was 0.4% 
and slightly higher in females at 0.6%. At 5 years, the sex 
difference increased where the cumulative incidence 
was 0.8% in males and 1.1% in females. For non-stroke 
mortality, the cumulative incidence at 2 years was similar 
in males at 17.6% and females at 17.4%. At 5 years, the 
cumulative incidence remained similar at 43.3% in males 
and 42.9% in females.
The cumulative incidence of stroke mortality decreased 
over time, where those diagnosed with ESKD in 2006–
2013 had the lowest cumulative incidence during 
follow-up (figure 2B). At 5 years, the cumulative inci-
dence increased to 1.6% in ≤1995, 0.9% in 1996–2005 
and 0.7% in 2006–2013. The cumulative incidence of 
non-stroke mortality showed a similar trend. At 5 years, 
the cumulative incidence increased to 46.3% in ≤1995, 
38.0% in 1996–2005 and 30.4% in 2006–2013.
dIsCussIOn
This multinational study represents the largest study of 
stroke mortality in people with ESKD to date, including 
more than 381 000 PYs follow-up in 60 823 people starting 
treatment for ESKD to evaluate risk factors associated 
with stroke mortality in the Australia and New Zealand. 
Our main finding was that women with ESKD were 41% 
Stroke death Non-stroke death
SHR (95% CI) P value SHR (95% CI) P value
  Other 1.03 (0.82 to 1.28) – 1.42 (1.37 to 1.47) –
The multivariate model was also adjusted for country. Global p values were test for heterogeneity.
Bold values indicate estimates with a significant association at 0.05 alpha level (ie, p value<0.05). 
BMI, body mass index; ESKD, end-stage kidney disease; HD, haemodialysis; PD, peritoneal dialysis.
Table 3 Continued 
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more likely to die from a stroke death compared with 
men with ESKD. There was a decreasing trend in stroke 
mortality risk over time, where patients with incident 
ESKD in ≤1995 nearly twice as likely to die of stroke death 
compared those starting ESKD treatment in 2006–2013. 
We also found that those with cerebrovascular disease 
were over twofold more likely to die of stroke compared 
with those without cerebrovascular disease. Other factors 
associated with an increased stroke mortality risk included 
older age, normal BMI (vs overweight or obese BMI), 
no previous malignancy, dialysis treatment compared 
transplant and hypertension/renal artery disease or 
diabetes as the cause of ESKD (vs glomerulonephritis/
IgA nephropathy). These risk factors highlight patients 
with ESKD at greater risk of stroke death that could be 
targeted in prevention strategies, particularly those with 
cerebrovascular disease and females.
Our findings suggest a sex difference in stroke mortality 
where women have at a greater risk of dying following a 
stroke compared with men. Women have also been shown 
to have a stroke incidence nearly twice that of men in the 
Australian ESKD population. This is unlike the Australian 
and New Zealand general population, where men have 
a higher stroke incidence but comparable death rate 
to women.20 21 Women may have confounding factors 
that place them at a greater risk of stroke death. In the 
general population, women are older at stroke onset, 
have poorer outcomes after stroke and are more likely 
to have atrial fibrillation and hypertension.22–25 Alter-
natively, stroke prevention may not be implemented in 
women as often as men. Previous studies in the general 
population have found that women were less likely to be 
prescribed antiplatelet therapy following an ischaemic 
stroke and less frequently treated with an oral anticoagu-
lant once diagnosed with atrial fibrillation.26 27 These gaps 
in care may also prevail in the ESKD population, however, 
no studies to date have specifically examined sex differ-
ences in stroke prevention among patients with ESKD. 
Whether a lack of stroke prevention strategies or other 
factors contribute to female patients with ESKD being at 
a greater risk of stroke and stroke death still needs further 
investigation.
Pre-existing cerebrovascular disease presents an oppor-
tunity for secondary prevention in the ESKD population, 
either with existing or novel interventions. Our findings 
are supported by previous studies of incident and recur-
rent strokes in the ESKD population.28–31 Studies in the 
UK found that patients with ESKD with prior cerebro-
vascular disease were 4.5 times more at risk of incident 
stroke.28 31 The mechanisms underlying cerebrovascular 
disease and ESKD are likely due to a combination of 
factors.32–35 First, CKD and cerebrovascular disease share 
common risk factors, including older age, diabetes, 
hypertension, obesity and smoking.33 34 Second, CKD-as-
sociated risk factors associated with CKD, such as chronic 
inflammation, oxidative stress and uraemic retention 
products, contribute to an excess risk of cerebrovascular 
disease.32 35 Third, the dialysis process itself could lead to 
an increased risk of stroke, such as hypoperfusion in HD 
and glucose degradation in PD.9 36 In transplant patients, 
graft function and the effect of albuminuria and eGFR may 
also modify their risk of stroke death.10 Until now cere-
brovascular disease prevention strategies implemented in 
the ESKD population have mainly been based on stroke 
interventions in the general population.33 37 38 Secondary 
stroke prevention can either target modifiable risk factors, 
such as hypertension and dyslipidaemia, or recommend 
the use of an anticoagulant or antiplatelet.38 39 However, 
the effectiveness of anticoagulant or antiplatelet therapy 
in the ESKD population is unclear as patients with ESKD 
are often under-represented or excluded from preven-
tion trials.33 The few observational studies in anticoag-
ulation therapy with warfarin suggested little evidence 
of preventing ischaemic strokes and increased the risk 
of major bleeding among patients with ESKD under-
going HD.40 41 Similarly, there is an absence of trial data 
on the safety and effectiveness of stroke thrombolysis in 
people with ESKD. A study examining nephrologist views 
on stroke thrombolysis showed that most had concerns 
about the bleeding risks and were uncertain about the 
overall benefits in patients with ESKD.42 However, our 
findings did suggest a decreasing trend in stroke mortality 
risk over time where those initiating ESKD treatment in 
recent years were less likely to die of stroke. This may 
have arisen from improved stroke prevention interven-
tions over time or better renal management. Further 
Figure 2 Estimate cumulative incidence of stroke and non-
stroke deaths, by: (A) sex; (B) year period of ESKD diagnosis. 
ESKD, end-stage kidney disease.
 on 13 M









pen: first published as 10.1136/bm





11De La Mata NL, et al. BMJ Open 2019;9:e026263. doi:10.1136/bmjopen-2018-026263
Open access
research is still needed to assess whether the effectiveness 
of secondary stroke prevention could be improved in the 
ESKD population.
There were similarities and differences in the risk factors 
associated with stroke and non-stroke mortality. Several 
risk factors were associated with an increased risk for both 
stroke and non-stroke death, including older age, earlier 
year of ESKD, normal BMI compared with overweight 
BMI, cerebrovascular disease, HD compared with trans-
plant and diabetes or hypertension/renal artery disease 
compared with glomerulonephritis/IgA nephropathy 
as cause of renal failure. Female sex was only associated 
with an increased risk of stroke death. While factors only 
associated with an increased risk of non-stroke death were 
underweight BMI compared with normal BMI, white 
racial background, coronary or peripheral artery disease, 
current or former smoker and glomerulonephritis/IgA 
nephropathy compared with polycystic kidney disease as 
cause of ESKD.
A major strength of our study was our large popu-
lation-based patient sample that included the entire 
ESKD population in Australia and New Zealand. We also 
conducted several sensitivity analyses which were rela-
tively consistent in the risk factors for stroke mortality. 
This suggests our main analysis was fairly robust and reli-
able. However, there were several limitations to our study. 
The limited data collected by ANZDATA did not allow us 
to evaluate whether secondary stroke prevention inter-
ventions were being used in patients with ESKD. In addi-
tion, previous studies have shown family history of stroke, 
blood pressure, atrial fibrillation and laboratory-related 
data (such as haemoglobin) are strongly associated with 
stroke, yet these data were not available in our patients 
with ESKD as it is not systematically collected by the 
ANZDATA registry. We also used data linkage to establish 
the cause of death and date of death. Australian patients 
were matched using probabilistic linkage to the national 
death registry, while New Zealand patients were matched 
via deterministic linkage. Probabilistic linkage can lead 
to patients being incorrectly linked and, subsequently, 
reporting an incorrect cause of death. The false positive 
rate is estimated at 5 per 1000 or 0.5%.43 Mismatched 
fact of death was high at 8% for Australian patients and 
6% for New Zealand patients. The national death regis-
tries would not have captured patient deaths if they had 
occurred outside of their registered country. However, 
relatively few patients (0.8%) were considered lost to 
follow-up in ANZDATA, where overseas death would be 
possible. Hence, it is unlikely that patients with ESKD 
moving overseas or between Australia and New Zealand 
would have contributed to reduced linkage quality. 
In addition, we used the underlying cause of death to 
define stroke deaths. We would, therefore, expect these 
stroke deaths to include patients who died of stroke and 
stroke complications. Any misclassification bias would be 
expected to be non-differential among people with ESKD 
and the general population. We used the Fine and Gray 
model to account for competing events of non-stroke 
deaths, which does not allow time-varying covariates. We 
were therefore unable to evaluate treatment modality 
switches during follow-up. Finally, the sensitivity analyses 
for risk factors associated with ischaemic stroke deaths 
and haemorrhagic stroke deaths separately had substan-
tially fewer stroke deaths than the overall main analysis. 
In particular, there were only 108 ischaemic stroke deaths 
which reduced the power to detect associated risk factors 
in the model and increased impression of SHR estimates. 
As such, we advise caution when interpreting these find-
ings to suggest risk factors for ischaemic stroke deaths are 
significantly different to haemorrhagic or all-cause stroke 
deaths in patients with ESKD.
In conclusion, our analysis describes risk factors for 
stroke mortality in the Australian and New Zealand ESKD 
population. Most factors that led to an increased risk of 
stroke death were non-modifiable, including older age, 
female sex, year of ESKD and cause of ESKD. The sex 
difference in stroke mortality in the ESKD population 
is not seen in the general population. This raises ques-
tions as to whether female patients with ESKD have other 
clinical characteristics that place them at a greater risk 
or whether prevention strategies are not prescribed 
in women as often as men. In addition, implementing 
prevention strategies in those with prior cerebrovascular 
disease has the potential to prevent secondary stroke in 
patients with ESKD. It is unclear whether stroke preven-
tion strategies are as effective in the ESKD population as 
in the general population. Further research into the use 
and effectiveness of stroke prevention in the ESKD popu-
lation is needed to evaluate means of reducing stroke 
mortality in those with cerebrovascular disease and in 
females.
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